These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31023141)

  • 1. Interchangeability Of Biological Drug Products-FDA Draft Guidance.
    Endrenyi L; Markus R
    J Biopharm Stat; 2019; 29(6):1003-1010. PubMed ID: 31023141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sowing confusion in the field: the interchangeable use of biosimilar terminology.
    McKinley L; Kelton JM; Popovian R
    Curr Med Res Opin; 2019 Apr; 35(4):619-621. PubMed ID: 30556742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars: policy, clinical, and regulatory considerations.
    Gottlieb S
    Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S2-8. PubMed ID: 18591712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Science of Biosimilars-Updating Interchangeability.
    Cavazzoni P; Yim S
    JAMA; 2024 Oct; 332(15):1235-1236. PubMed ID: 39292484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Analysis of Biosimilar Switching Studies.
    Chow SC; Lee SJ
    Pharmaceut Med; 2019 Oct; 33(5):379-388. PubMed ID: 31933227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of the FDA draft guidance on biosimilars for clinicians: what we know and don't know.
    Li E; Hoffman JM
    J Natl Compr Canc Netw; 2013 Apr; 11(4):368-72. PubMed ID: 23584340
    [No Abstract]   [Full Text] [Related]  

  • 9. Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical Study.
    He K; Chen H; Gwise T; Casak S; Lemery S; Keegan P; Pazdur R; Sridhara R
    Clin Cancer Res; 2016 Nov; 22(21):5167-5170. PubMed ID: 27582485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
    O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
    Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacist Substitution of Biological Products: Issues and Considerations.
    Li E; Ramanan S; Green L
    J Manag Care Spec Pharm; 2015 Jul; 21(7):532-9. PubMed ID: 26108377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Expectations for Demonstrating Interchangeability.
    Chance K
    Ther Innov Regul Sci; 2018 May; 52(3):369-373. PubMed ID: 29714562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars 101: considerations for U.S. oncologists in clinical practice.
    Camacho LH; Frost CP; Abella E; Morrow PK; Whittaker S
    Cancer Med; 2014 Aug; 3(4):889-99. PubMed ID: 24810680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009.
    Carver KH; Elikan J; Lietzan E
    Food Drug Law J; 2010; 65(4):671-818, ii. PubMed ID: 24479247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demystifying biosimilars: development, regulation and clinical use.
    Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
    Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars: Here and Now.
    Lemery SJ; Esteva FJ; Weise M
    Am Soc Clin Oncol Educ Book; 2016; 35():e151-7. PubMed ID: 27249717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations.
    Dranitsaris G; Amir E; Dorward K
    Drugs; 2011 Aug; 71(12):1527-36. PubMed ID: 21861538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars: where we were and where we are.
    Challand R; Gorham H; Constant J
    J Biopharm Stat; 2014; 24(6):1154-64. PubMed ID: 25036475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comments on the FDA draft guidance on biosimilar products.
    Chow SC; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):364-9. PubMed ID: 22903309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.